In Menarini Deal, Silicon Bio Sees Opportunities for Clinical Validation, Menu Expansion | GenomeWeb

Silicon Biosystems believes that its recent acquisition by the Menarini Group, an Italian pharmaceutical company, will provide it with the support to move its cell array platform into the clinical market.

The Bologna, Italy-based firm also sees the Menarini deal as a means to grow, and as such plans to add sales and support personnel, as well as expand its R&D team, Bob Proulx, president of Silicon Bio's San Diego-based US subsidiary, told BioArray News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.